Insights
Search Results
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
1.13.26
Wilson Sonsini Advises Proxima on $80 Million Seed Financing
On January 13, 2026, Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, announced an oversubscribed $80 million Seed financing.
Client Highlights
12.06.24
Wilson Sonsini Advises Dewpoint Therapeutics on Strategic Research Collaboration with MTPC
On December 4, 2024, Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced that it has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), effective December 1, 2024.
News Articles
4.24.23
Morgan Brown Named a 2023 Up & Coming Lawyer “Excellence in the Law” Honoree
In March, Wilson Sonsini associate Morgan Brown was selected as one of Massachusetts Lawyers Weekly’s 2023 Up & Coming Lawyers “Excellence in the Law” honorees. Each year, the publication celebrates up and coming lawyers and honorees for excellence in pro bono, legal journalism, ADR, marketing, firm administration, and paralegal work. Morgan is a member of the technology transactions group at the firm, where her practice focuses on the life sciences industry and advising clients on various intellectual property and commercial transactions. Honorees will be recognized at a dinner in Boston on May 16.
Client Highlights
10.19.22
Wilson Sonsini Advises Zymeworks on Exclusive Licensing Agreement with Jazz Pharmaceuticals
On October 19 2022, Zymeworks BC Inc. and Jazz Pharmaceuticals Ireland Ltd. announced that they entered into an exclusive license agreement to develop and commercialize zanidatamab. Under that arrangement, Jazz will receive an exclusive license from Zymeworks to develop and commercialize zanidatamab in the United States, Europe, Japan, and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene, Ltd.
Client Highlights
9.26.22
Wilson Sonsini Advises RA Capital Management on Rivus Pharmaceuticals' $132 Million Series B
On September 22, 2022, Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG, and existing investors Longitude Capital, Medicxi, and RxCapital. Wilson Sonsini Goodrich & Rosati advised RA Capital in the transaction.
Client Highlights
10.22.21
Wilson Sonsini Represents Babylon in $4.2 Billion Merger with Alkuri Global
On October 21, 2021, Babylon Holdings Limited, one of the world's fastest-growing digital healthcare companies, announced that it has completed its business combination with Alkuri Global Acquisition Corp., a special purpose acquisition company. Babylon's Class A ordinary shares and its warrants will begin trading on the New York Stock Exchange on October 22, 2021 under the new ticker symbols "BBLN" and "BBLN.W", respectively. Wilson Sonsini Goodrich & Rosati represented Babylon in the merger.
Client Highlights
5.12.21
Wilson Sonsini Advises RA Capital Management on Corporate, IP Matters Related to Forge Biologics' $120 Million Series B Financing
On April 29, 2021, Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace. Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. Forge will use the proceeds of this Series B financing to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity, as well as operate its subsidiaries that are advancing novel AAV gene therapy programs. For more information on the Forge Biologics transaction, please see the company's press release.
Client Highlights
3.29.21
Firm Advises 4D pharma on Merger with Longevity Acquisition Corporation and Nasdaq ADS Listing
On March 22, 2021, 4D pharma plc, a Leeds, UK-based pharmaceutical company leading the development of Live Biotherapeutic products (LBPs)—a novel class of drugs derived from the microbiome—announced the completion of its merger with Longevity Acquisition Corporation, a Nasdaq-listed Special Purpose Acquisition Company (SPAC). Wilson Sonsini Goodrich & Rosati advised 4D pharma on corporate and intellectual property matters related to the cross-border transaction.
The merger was structured as an acquisition of the SPAC by 4D pharma, a concurrent global PIPE financing, and the concurrent Nasdaq listing of 4D pharma American Depositary Shares (ADSs) and warrants. As a result, 4D pharma ADSs now trade on the Nasdaq Global Market under the ticker symbol “LBPS” and its warrants now trade on the Nasdaq Global Market under the ticker symbol “LBPSW.” 4D pharma ordinary shares continue to be admitted to trading on the London Stock Exchange’s AIM market under the ticker symbol “DDDD.”
The merger was structured as an acquisition of the SPAC by 4D pharma, a concurrent global PIPE financing, and the concurrent Nasdaq listing of 4D pharma American Depositary Shares (ADSs) and warrants. As a result, 4D pharma ADSs now trade on the Nasdaq Global Market under the ticker symbol “LBPS” and its warrants now trade on the Nasdaq Global Market under the ticker symbol “LBPSW.” 4D pharma ordinary shares continue to be admitted to trading on the London Stock Exchange’s AIM market under the ticker symbol “DDDD.”
Client Highlights
3.15.21
Firm Advises Prometheus Biosciences on IP Matters Related to Initial Public Offering
On March 11, 2021, Prometheus Biosciences, a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease, announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Prometheus. The shares began trading on the Nasdaq Global Select Market on March 12 under the ticker symbol “RXDX.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prometheus, are expected to be $190 million. Wilson Sonsini Goodrich & Rosati is advising Prometheus on intellectual property matters related to the transaction.
The offering is expected to close on March 16, subject to the satisfaction of customary closing conditions. In addition, Prometheus has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. SVP Leerink, Credit Suisse, Stifel, and Guggenheim Securities are acting as joint bookrunning managers for the offering.
The Wilson Sonsini team advising Prometheus on intellectual property matters related to the offering includes Sara Pennebaker, Alicia Umpierre, Erin Boyle Anderson, Morgan Brown, Jacob Panangat, Brian Brown, Farah Gerdes, and Matthew Bresnahan.
For more information, please see Prometheus Biosciences’ press release.
The offering is expected to close on March 16, subject to the satisfaction of customary closing conditions. In addition, Prometheus has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. SVP Leerink, Credit Suisse, Stifel, and Guggenheim Securities are acting as joint bookrunning managers for the offering.
The Wilson Sonsini team advising Prometheus on intellectual property matters related to the offering includes Sara Pennebaker, Alicia Umpierre, Erin Boyle Anderson, Morgan Brown, Jacob Panangat, Brian Brown, Farah Gerdes, and Matthew Bresnahan.
For more information, please see Prometheus Biosciences’ press release.
Client Highlights
Wilson Sonsini Advises DCx on Agreement with Repare Therapeutics
On May 1, 2025, DCx Biotherapeutics, a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions, announced an agreement with Repare Therapeutics to in-license its discovery platform and intellectual property, retain talent, and acquire laboratory facilities and equipment in Montreal. Wilson Sonsini Goodrich & Rosati advised DCx on the transaction.
The agreement, effective May 1, 2025, aims to enhance DCx's capabilities in developing Multi-Modal Antibody Drug Conjugates (MM-ADCs) targeting genetically-defined cancers. Repare will receive upfront cash payments, equity in DCx, a board nominee, as well as out-licensing, clinical, and commercial milestones, along with low single-digit tiered sales royalties for products developed from Acquired Programs and Acquired Targets.
The Wilson Sonsini team that advised DCx includes:
The agreement, effective May 1, 2025, aims to enhance DCx's capabilities in developing Multi-Modal Antibody Drug Conjugates (MM-ADCs) targeting genetically-defined cancers. Repare will receive upfront cash payments, equity in DCx, a board nominee, as well as out-licensing, clinical, and commercial milestones, along with low single-digit tiered sales royalties for products developed from Acquired Programs and Acquired Targets.
The Wilson Sonsini team that advised DCx includes: